openPR Logo
Press release

Tyrosine Protein Kinase ITK/TSK - Pipeline Review, H1: Pharmaceuticals Industry Research Report - MRH

06-27-2017 03:04 PM CET | Health & Medicine

Press release from: electronics market research reports- [MRH]

Market Research Hub

Market Research Hub

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) pipeline Target constitutes close to 9 molecules. Out of which approximately 9 molecules are developed by Companies. The latest report Tyrosine Protein Kinase ITKTSK - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Request For Free Sample @ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1177493

“Tyrosine Protein Kinase ITK/TSK” - Tyrosine-protein kinase ITK/TSK or interleukin-2-inducible T-cell kinase or simply ITK is a protein encoded by the ITK gene. It plays an essential role in regulation of the adaptive immune response. When antigen presenting cells (APC) activate T-cell receptor (TCR) a series of phosphorylation lead to the recruitment of ITK to the cell membrane, stimulate TCR receptor, where it is phosphorylated by LCK. Phosphorylation leads to ITK autophosphorylation and full activation. It regulates the development, function and differentiation of conventional T-cells and nonconventional NKT-cells. The molecules developed by companies in Filing rejected/Withdrawn, Phase II, Preclinical and Discovery stages are 1, 2, 4 and 2 respectively.

Report covers products from therapy areas Oncology, Immunology, Gastrointestinal and Respiratory which include indications Autoimmune Disorders, Rheumatoid Arthritis, Allergies, Angiosarcoma, Asthma, Chondrosarcoma, Chronic Inflammation, Colorectal Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Follicular Thyroid Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Inflammation, Liposarcoma, Merkel Cell Carcinoma, Metastatic Breast Cancer, Metastatic Renal Cell Carcinoma, Neuroblastoma, Osteosarcoma, Ovarian Cancer, Papillary Thyroid Cancer, Peritoneal Cancer, Psoriasis, Recurrent Glioblastoma Multiforme (GBM), Rhabdomyosarcoma, Soft Tissue Sarcoma, Thyroid Cancer and Ulcerative Colitis.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

Browse Full Report With TOC @ http://www.marketresearchhub.com/report/tyrosine-protein-kinase-itktsk-interleukin-2-inducible-t-cell-kinase-or-t-cell-specific-kinase-or-kinase-emt-or-tyrosine-protein-kinase-lyk-or-itk-or-ec-27102-pipeline-review-h1-2017-report.html

- The report reviews key players involved in Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Arrien Pharmaceuticals LLC
Confluence Life Sciences Inc
Corvus Pharmaceuticals Inc
Genentech Inc
Japan Tobacco Inc
Novartis AG
Principia Biopharma Inc
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine.
Continue….

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1177493

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Details:

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email: press@marketresearchhub.com
Website: http://www.marketresearchhub.com/
Read More Related News: https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Tyrosine Protein Kinase ITK/TSK - Pipeline Review, H1: Pharmaceuticals Industry Research Report - MRH here

News-ID: 598121 • Views:

More Releases from electronics market research reports- [MRH]

Global Solar Traffic Products Market Insights and Trends to 2022
Global Solar Traffic Products Market Insights and Trends to 2022
In this report, the global Solar Traffic Products market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Request A Free
Global Smart Classroom Market Research, Production, Revenue, Forecasts Until 2022-
Global Smart Classroom Market Research, Production, Revenue, Forecasts Until 202 …
To understand the electronics industry status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Global Smart Classroom Market Research Report 2017”, to its vast database. This study offers data about the prime regions operating in the different sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR until 2022. Request Free
Global Shotgun Microphone Market Trends, Production, Revenue, Forecasts to 2022
Global Shotgun Microphone Market Trends, Production, Revenue, Forecasts to 2022
: To understand the electronics industry status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Global Shotgun Microphone Market Research Report 2017”, to its vast database. This study offers data about the prime regions operating in the different sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR until
Global Permanent Magnet Contactors Market Size, Status and Forecast 2022: By Production, Consumption, Revenue, Market share and Growth Rate
Global Permanent Magnet Contactors Market Size, Status and Forecast 2022: By Pro …
In this report, the global Permanent Magnet Contactors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. The report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Request A Free

All 5 Releases


More Releases for Kinase

Cancer Tyrosine Kinase Inhibitors Market Cancer Tyrosine Kinase Clinical Pipelin …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. The Journey: Genesis to Present of Tyrosine Kinase Inhibitors 2. Tyrosine Kinase: An Overview 3. Tyrosine Kinases Inhibitors: Promising Tools for Targeted Cancer Therapies 4. Types of Tyrosine Kinase Receptors 4.1 Epidermal Growth Factor Receptor 4.1.1 Types of Epidermal Growth Factor Receptor 4.1.2 Epidermal Growth Factor Receptor & Ligands 4.1.3
Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Bet …
According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. Request Free Sample Report - http://www.marketresearchhub.com/enquiry.php?type=S&repid=1157712 Mitogen Activated Protein Kinase Kinase Kinase 7
Tyrosine Protein Kinase JAK3 (Janus Kinase 2 or JAK3 or EC 2.7.10.2) – Pharmac …
Market Research Hub report titled ‘Tyrosine Protein Kinase JAK3 Pipeline’ (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline …
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies. The latest report Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with
Orbis Research - Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Cataly …
Description: Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 9
Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stres …
Market Reports Center’s, ‘Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c or MAPK8 or EC 2.7.11.24) - Pipeline Review, H2 2016’, provides in depth analysis on Mitogen Activated Protein Kinase 8 (c Jun N Terminal Kinase 1 or JNK 46 or Stress Activated Protein Kinase JNK1 or Stress Activated Protein Kinase 1c